Amgen Inc.

AMGN

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (Cinacalcet): Dec 2000. Short interest: 2.3% of float.

Drug Manufacturers - GeneralCEO: Robert A. BradwayIPO: 1983Website ↗

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Catalysts

Phase 2Q4 2000CinacalcetPrimary HyperparathyroidismNCT03776058

Primary: Number of Participants with Adverse Events (4 weeks)Enrollment:10/10RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2003darbepoetin alfaAnemia, Non-Myeloid MalignanciesNCT00540696

Primary: Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score (baseline)Enrollment:Target 300RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2006EtanerceptPsoriasisNCT00078819

Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 (Baseline and week 12)Enrollment:211/211RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2008DenosumabGCT, Giant Cell Tumor of BoneNCT00396279

Primary: Percentage of Participants With Giant Cell Tumor Response (From enrollment until 25 weeks)Enrollment:37/37NA, TREATMENT

Phase 3ApprovedQ3 2008HZT-501Peptic UlcerNCT00450658

Primary: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy. (24 weeks)Enrollment:627/627RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3PositiveQ4 2008Medical Standard of Care for ITPIdiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)NCT00415532

Primary: Number of Participants With Splenectomy During 52-Week Treatment Period (52 weeks)Enrollment:234/234RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2009MR prednisoneRheumatoid ArthritisNCT00650078

Primary: ACR 20 Response Rate at Visit 4 (Week 12)Enrollment:350/350Sites: 52RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2009DenosumabBone MetastasesNCT00321464

Primary: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) (Up to 34 months)Enrollment:2,049/2,049RANDOMIZED, TRIPLE, SUPPORTIVE_CARE

Phase 2Q4 2009PlaceboMDS, Myelodysplastic Syndromes, ThrombocytopeniaNCT00321711

Primary: Occurrence of a Clinically Significant Thrombocytopenic Event (Treatment period (up to 20 weeks))Enrollment:69/69RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2PositiveQ1 2012BlinatumomabB-ALLNCT01209286

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment (Within the first 2 cycles of treatment, 12 weeks)Enrollment:36/36Sites: 9NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2012MP-376 (Levofloxacin Solution for Inhalation)Cystic FibrosisNCT01270347

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (From start of study until end of the study (up to 168 days))Enrollment:282/282Sites: 130RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2012CarfilzomibMultiple Myeloma, Renal InsufficiencyNCT00721734

Primary: Clearance (CL) of Carfilzomib on Day 1 of Cycle 1 (Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.)Enrollment:50/50Sites: 5NA, TREATMENT

Phase 3Q1 2013CetuximabMetastatic Colorectal CancerNCT01001377

Primary: Overall Survival (From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.)Enrollment:1,010/1,010Sites: 152RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2013AMG 747SchizophreniaNCT01568216

Primary: Change from baseline to week 12 in negative symptoms, as measured by the NSA-16 total score (12 Weeks)Enrollment:121/121Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2014EtelcalcetideHyperparathyroidism, SecondaryNCT01785849

Primary: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).)Enrollment:508/508Sites: 118RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2014ApremilastPsoriasis, Psoriatic ArthritisNCT01690299

Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline (Baseline to Week 16)Enrollment:250/250Sites: 82RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2015BlinatumomabRelapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaNCT02013167

Primary: Overall Survival (From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.)Enrollment:405/405Sites: 117RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2016AMG 386Fallopian Tube Cancer, Ovarian Cancer, Peritoneal CancerNCT01493505

Primary: Progression free survival (3 years)Enrollment:1,015/1,015Sites: 310RANDOMIZED, TRIPLE, TREATMENT

Phase 2May 17, 2016intensive chemotherapy and hematopoietic stem cell rescuePrimary Central Nervous System LymphomaNCT00863460

Primary: 2-years progression-free survival in each arm (2 years after inclusion)Enrollment:140/140Sites: 23RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2016DenosumabSteroid-induced Osteopor, Glucocorticoid-induced OsteporNCT01575873

Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) (Baseline and month 12)Enrollment:795/795Sites: 99RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2016ErenumabMigraineNCT02483585

Primary: Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase)Enrollment:577/577Sites: 76RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2016Talimogene laherparepvecMelanomaNCT01740297

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (The DLT evaluation period was 6 weeks from the initial administration of ipilimumab (week 6 to 12).)Enrollment:217/217Sites: 40RANDOMIZED, TREATMENT

Phase 3Q1 2017interferon γ-1bFriedreich's AtaxiaNCT02797080

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs (Baseline/Day 1 (Week 28 Follow-Up Visit for Study HZNP-ACT-302 ([NCT02593773]) through end of study; mean (SD) duration of treatment was 99.2 (58.48) days.)Enrollment:38/38Sites: 4NA, TREATMENT

Phase 3NegativeQ3 2017PlaceboBreast CancerNCT01077154

Primary: Bone Metastasis-free Survival (BMFS) (From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.)Enrollment:4,509/4,509Sites: 459RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jul 5, 2018carfilzomibSmoldering Multiple MyelomaNCT02415413

Primary: Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT (4 months)Enrollment:Target 90Sites: 16NA, TREATMENT

Phase 2Q4 2019Consolidation with 4 cycles of CarCyDexMultiple MyelomaNCT02315716

Primary: Response rate (Within 4 weeks of the end of induction treatment)Enrollment:281/281Sites: 20RANDOMIZED, TREATMENT

Phase 2Jul 30, 2022CarfilzomibMultiple MyelomaNCT04430894

Primary: Complete Response (CR + Stringent CR) Rate (112 Days)Enrollment:50/50Sites: 3NON_RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ3 2022AMG 510KRAS p, G12c Mutated /Advanced Metastatic NSCLCNCT04303780

Primary: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months)Enrollment:345/345Sites: 274RANDOMIZED, TREATMENT

Phase 2Q4 2022CarfilzomibRelapsed or Refractory Multiple MyelomaNCT04191616

Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) (From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks)Enrollment:54/54Sites: 46NA, TREATMENT

Phase 2Feb 7, 2023Talimogene LaherparepvecSoft Tissue SarcomaNCT04599062

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (14 weeks)Enrollment:8/8Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Jun 28, 2023Carfilzomib, lenalidomide, dexamethasone (KRd) + DaratumumabMultiple MyelomaNCT04113018

Primary: Number of Participants With Complete Response or Stringent Complete Response to Induction (From enrollment to best response determined at the end of induction (8 28-day cycles); the median length of induction was 32 weeks)Enrollment:39/39Sites: 1NA, TREATMENT

Phase 2Sep 26, 2023CarfilzomibSmoldering Multiple MyelomaNCT03289299

Primary: Stringent complete response rate (During treatment)Enrollment:87/87Sites: 10NA, TREATMENT

Phase 3Q1 2024RomiplostimChemotherapy-induced ThrombocytopeniaNCT03362177

Phase 2Q1 2024CarfilzomibMultiple Myeloma, Smoldering Multiple MyelomaNCT03815279

Primary: Rate of MRD negativity (36 months after study enrollment)Enrollment:Target 80Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Feb 28, 2024BlinatumomabB-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, ChildhoodNCT04746209

Phase 3PositiveQ2 2024InebilizumabIg G4 Related DiseaseNCT04540497

Phase 3Q2 2024inebilizumabMyasthenia GravisNCT04524273

Phase 2NegativeQ3 2024HZN-825Idiopathic Pulmonary FibrosisNCT05032066

Phase 2Aug 1, 2024PanitumumabTreatment Related CancerNCT04034173

Phase 3Sep 30, 2024IsatuximabMultiple MyelomaNCT04934475

Phase 3Q1 2025TarlatamabSmall Cell Lung Cancer (SCLC)NCT05740566

Phase 2Q1 2025TarlatamabExtensive Stage Small Cell Lung CancerNCT06502977

Primary: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off)Enrollment:32/32Sites: 12NA, TREATMENT

Phase 2Apr 15, 2025IsatuximabMultiple Myeloma in Relapse, Multiple Myeloma, RefractoryNCT04287855

Phase 2Jun 20, 2025Talimogene LaherparepvecSoft Tissue Sarcoma, Sarcoma, Soft TissueNCT06660810

Phase 3Q2 2025BemarituzumabGastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT05052801

Phase 2Jun 24, 2025CarfilzomibPlasma Cell MyelomaNCT03756896

Phase 3Jun 28, 2025FOLFOX regimenColorectal CancerNCT03635021

Phase 3Q3 2025SotorasibColorectal Cancer (CRC)NCT05198934

Phase 2Jul 22, 2025Talimogene Laherparepvec (T-VEC)Sarcoma, Epithelioid Sarcoma, Cutaneous AngiosarcomaNCT03069378

Phase 3Q3 2025EvolocumabCoronary Heart Disease (CHD)NCT03872401

Phase 3Jul 31, 2025Carfilzomib Lenalidomide DexamethasoneMultiple MyelomaNCT04483739

Phase 2Aug 7, 2025RegorafenibColorectal CancerNCT04787341

Phase 2Q4 2025Maridebart CafraglutideType 2 Diabetes Mellitus (T2DM)NCT06660173

Primary: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Baseline to Week 24)Enrollment:409/409Sites: 96RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2025BemarituzumabGastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT05111626

Phase 3Q4 2025Erenumab Dose 1MigraineNCT03836040

Phase 3Q4 2025ApremilastPlaque PsoriasisNCT05565560

Phase 2Q4 2025BemarituzumabGastric Cancer, Gastroesophageal Junction CancerNCT05322577

Phase 2Q1 2026BlinatumomabB Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic LeukemiaNCT06054113

Phase 3Q1 2026TeprotumumabThyroid Eye DiseaseNCT06248619

Phase 2Q1 2026HZN-1116Sjogren's SyndromeNCT06312020

Phase 2Q1 2026BlinatumomabAcute Lymphoblastic Leukemia, Philadelphia Chromosome-PositiveNCT04329325

Phase 3Q2 2026RocatinlimabPrurigo NodularisNCT06527404

Phase 2Q2 2026RocatinlimabAsthmaNCT06376045

Phase 3Q2 2026RomiplostimChemotherapy-induced ThrombocytopeniaNCT03937154

Phase 2Q2 2026AnvumetostatAdvanced MTAP-null Solid TumorsNCT05094336

Phase 2Q2 2026sotorasibKRAS p.G12C Mutant Advanced Solid TumorsNCT03600883

Phase 3Q2 2026RocatinlimabAtopic DermatitisNCT05882877

Phase 2Jun 30, 2026Blinatumomab 9ugAcute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic LeukaemiaNCT03114865

Primary: Overall survival at two years post first treatment cycle (2 years)Enrollment:44/44Sites: 1NA, TREATMENT

Phase 2Q2 2026DaratumumabMyeloma, Multiple MyelomaNCT03500445

Phase 2Q2 2026avutometinib and sotorasibNon Small Cell Lung Cancer, KRAS Activating MutationNCT05074810

Phase 3Jul 14, 2026TezepelumabEosinophilic EsophagitisNCT05583227

Phase 3Q3 2026ApremilastPlaque PsoriasisNCT06088199

Phase 3Q3 2026DazodalibepSjogren's SyndromeNCT06104124

Phase 3Sep 30, 2026PrednisoneAcute Lymphoblastic Leukemia, Acute Lymphoblastic LymphomaNCT03117751

Phase 3Q4 2026DazodalibepSjögren's Syndrome (SS)NCT06245408

Phase 3Q4 2026ABP 234Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06430866

Phase 2Q4 2026TarlatamabRelapsed/Refractory Small Cell Lung CancerNCT05060016

Primary: Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator (Up to a maximum of 61 months)Enrollment:222/222Sites: 80RANDOMIZED, TREATMENT

Phase 2Q4 2026RomiplostimLymphoma Patients, ThrombocytopeniaNCT04673266

Phase 3Q1 2027Ocrelizumab (US)Relapsing-remitting Multiple Sclerosis (RRMS)NCT06700343

Phase 3Q1 2027Maridebart cafraglutideType 2 Diabetes Mellitus (T2DM), Obesity, OverweightNCT06858878

Phase 3Q1 2027Maridebart CafraglutideObesityNCT06858839

Phase 2Q1 2027Trastuzumab + PaclitaxelHER2-positive Breast Cancer, Operable Breast CancerNCT03571633

Phase 2Feb 1, 2027BortezomibMultiple MyelomaNCT04268498

Phase 2Q1 2027AMG 732Thyroid Eye DiseaseNCT06401044

Phase 2Mar 2, 2027RomosozumabOsteoporosis, Post-menopausalNCT06973109

Phase 2Q1 2027Romosozumab Prefilled Syringe [Evenity]Premenopausal Idiopathic OsteoporosisNCT04800367

Phase 2Q2 2027InebilizumabNeuromyelitis Optica Spectrum DisorderNCT05549258

Phase 2Apr 15, 2027TarlatamabMetastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced High-grade MTCNCT07016230

Phase 3Q2 2027Maridebart cafraglutideObesity DiseaseNCT06987695

Phase 2Q2 2027DaratumumabMultiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in RelapseNCT04176718

Phase 3Q2 2027RomosozumabOsteogenesis ImperfectaNCT05972551

Phase 3Q2 2027SotorasibNon-Small Cell Lung Cancer (NSCLC)NCT05920356

Phase 3Q2 2027EtelcalcetideSecondary HyperparathyroidismNCT03969329

Primary: Percent Change From Baseline in iPTH at Weeks 20 to 26 (Week 20 to 26)Enrollment:Target 24Sites: 23NA, TREATMENT

Phase 3Q3 2027TarlatamabExtensive-Stage Small-Cell Lung Cancer, Small-Cell Lung CancerNCT06211036

Phase 2Aug 31, 2027TarlatamabMetastatic Prostate CancerNCT07111507

Phase 2Q3 2027Maridebart cafraglutideOverweight or Obesity and Elevated Liver FatNCT07441252

Phase 3Q3 2027Maridebart cafraglutideObstructive Sleep ApneaNCT07226765

Phase 3Q3 2027Maridebart cafraglutideObesity, Obstructive Sleep ApneaNCT07225686

Phase 2Q3 2027bemarituzumab, paclitaxel, ramucirumabMetastatic Gastro-esophageal AdenocarcinomaNCT06680622

Primary: Objective response rate (ORR) (from date of enrollment to date of last response acc. to RECIST v1.1 or death due to any cause, through study completion, up to 33 months)Enrollment:Target 126Sites: 35NON_RANDOMIZED, TREATMENT

Phase 3Q3 2027BlinatumomabAcute Lymphoblastic Leukemia, Mixed Phenotype Acute LeukemiaNCT05327894

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 2Oct 20, 2027AMG 510Lung CancerNCT05118854

Phase 2Oct 31, 2027CarboplatinBreast Carcinoma, Breast Lump, EdemaNCT02876107

Phase 2Oct 31, 2027Interferon gamma-1bAcute Myeloid Leukemia, Myelodysplastic SyndromesNCT06529731

Phase 2Q4 2027BlinatumomabB Cell Precursor Acute Lymphoblastic LeukemiaNCT04521231

Phase 2Nov 30, 2027BlinatumomabAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein ExpressionNCT03263572

Phase 3Q4 2027Maridebart cafraglutideObesity, OverweightNCT07684235

Phase 2Dec 31, 2027TarlatamabExtensive Stage Lung Small Cell CarcinomaNCT07423585

Phase 2Dec 31, 2027TarlatamabExtrapulmonary Small Cell Carcinoma and Neuroendocrine CarcinomaNCT06816394

Phase 2Dec 31, 2027Treatment with blinatumomab given subcutaneously.Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic LeukemiaNCT07301424

Phase 2Q1 2028SotorasibAdvanced Solid TumorsNCT07172919

Phase 3Q1 2028Maridebart CafraglutideObesity or OverweightNCT07575399

Phase 3Q1 2028ABP 234Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721

Phase 3Q1 2028ABP 206MelanomaNCT06054555

Phase 2Q1 2028AMG 732Thyroid Eye DiseaseNCT07438405

Phase 2Mar 3, 2028TarlatamabAstrocytic Tumor, Oligodendroglial TumorNCT06776250

Phase 3Q1 2028ApremilastActive Juvenile Psoriatic ArthritisNCT04804553

Primary: Number of Participants who Achieve American College of Rheumatology Pediatric (ACR) Pedi 30 Response at Week 16 (Baseline to Week 16)Enrollment:Target 60Sites: 45RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2028PlaceboAtherosclerotic Cardiovascular DiseaseNCT05581303

Phase 3Q2 2028Osteogenesis ImperfectaNCT07366086

Phase 2Apr 24, 2028Tarlatamab treatmentDLL3-expressing Tumors, Advanced TumorsNCT06788938

Phase 3Q2 2028PegloticaseUncontrolled GoutNCT07388498

Primary: Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24 (Month 6 (Weeks 20, 21, 22, 23, and 24))Enrollment:Target 270Sites: 25RANDOMIZED, DOUBLE, TREATMENT

Phase 3May 31, 2028TezepelumabAsthmaNCT06023589

Phase 2Q2 2028DexamethasoneAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaNCT06533748

Phase 3Q2 2028OlpasiranCardiovascular DiseaseNCT07293260

Phase 3Q2 2028Maridebart cafraglutideHeart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, ObesityNCT07037459

Phase 3Q2 2028Maridebart CafraglutideAtherosclerotic Cardiovascular Disease, Overweight, ObesityNCT07037433

Phase 2Jul 1, 2028Belantamab mafodotinMultiple Myeloma, Relapse Multiple MyelomaNCT05789303

Phase 2Q3 2028InebilizumabSystemic Lupus Erythematosus, Active Refractory Rheumatoid ArthritisNCT06570798

Phase 2Q3 2028Carfilzomib + IbrutinibWaldenstrom MacroglobulinemiaNCT04263480

Phase 3Q3 2028FOLFIRI RegimenMetastatic Colorectal CancerNCT06252649

Phase 3Q3 2028AvacopanVasculitisNCT06321601

Phase 2Q4 2028anvumetostatMTAP-deleted NSCLCNCT06593522

Phase 2Q4 2028BlinatumomabRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic LeukemiaNCT07134088

Primary: Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs) (Up to 29 days)Enrollment:Target 104Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Q4 2028DexamethasoneLymphoblastic LeukemiaNCT05848687

Phase 2Q4 2028TarlatamabAdvanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary OriginNCT07061080

Phase 3Q1 2029XaluritamigMetastatic Castration-resistant Prostate CancerNCT06691984

Phase 3Q1 2029TarlatamabSmall-cell Lung Cancer, Extensive Stage Small-cell Lung CancerNCT07005128

Phase 3Q1 2029EtelcalcetideSecondary Hyperparathyroidism, Chronic Kidney DiseaseNCT03633708

Phase 2Q1 2029Blinatumomab InjectionB-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALLNCT07313852

Phase 2Q1 2029TarlatamabSmall Cell Lung Cancer (SCLC)NCT06745323

Phase 3Mar 13, 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06878261

Phase 3Mar 13, 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06883305

Phase 2Q2 2029Carfilzomib, Lenalidomide, Dexamethasone, Belantamab MafodotinMultiple MyelomaNCT04822337

Primary: Establish Maximum Tolerated Dose (MTD) (time to complete Cycle 1 (28 days))Enrollment:Target 70Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Q3 2029Subcutaneous BlinatumomabCD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)NCT07222579

Phase 3Q3 2029BlinatumomabNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)NCT04994717

Phase 2Q4 2029TarlatamabExtensive Stage Lung Small Cell CancerNCT07203053

Phase 2Q4 2029TarlatamabGlioma, CNS Tumor, Adult, CNS Tumor, ChildhoodNCT07243470

Phase 3Q4 2029DazodalibepSjögren's SyndromeNCT06747949

Phase 3Q1 2030XaluritamigMetastatic Castration-resistant Prostate CancerNCT07213674

Phase 3Q1 2030ApremilastBehçet DiseaseNCT04528082

Phase 2Q1 2030InebilizumabGeneralized Myasthenia GravisNCT06987539

Phase 3Q2 2030BlinatumomabPhiladelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic LeukemiaNCT07223190

Phase 3Q2 2030TarlatamabLimited Stage Small Cell Lung Cancer, Small Cell Lung CancerNCT06117774

Phase 2Q2 2030TarlatamabMelanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated CarcinomaNCT06814496

Phase 3Q3 2030AvacopanGranulomatosis With Polyangiitis, Wegener's, GPANCT07176546

Phase 2Oct 12, 2030BlinatumomabPhase 2 Study, Blinatumomab, Acute Lymphoblastic LeukemiaNCT07192237

Phase 2Q2 2031InebilizumabImmunoglobulin G4-related DiseaseNCT07222553

Phase 3Q3 2031InebilizumabAutoimmune Hepatitis, AIHNCT07598825

Phase 2Sep 30, 2031BlinatumomabB-cell Acute Lymphoblastic LeukemiaNCT07153796

Phase 2Sep 30, 2031BlinatumomabPhase II Clinical Trial, Blinatumomab, OlverembatinibNCT07178912

Phase 3Q4 2031OlpasiranCardiovascular DiseaseNCT07136012

Phase 3Q2 2033Omitted DoxorubicinLeukemia, Acute LymphoblasticNCT04307576

Phase 3Q1 2036ApremilastBehçet's Disease, Juvenile Psoriatic ArthritisNCT05767047

Phase 2TBDFilgrastimHIV Infections, CytopeniasNCT00002126

Enrollment:Target 250Sites: 22TREATMENT

Phase 2TBDABX-EGF (panitumumab)Metastatic Colorectal CancerNCT00327119

Enrollment:Target 50NON_RANDOMIZED, TREATMENT

Amgen Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research